Certolizumab Pegol not checked
UCB Biopharma SRL · CDP870
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “* pharmaceutical form: solution for infusion in prefilled syringe * concentration: 200 mg/mL * route of administration: subcutaneous”In the company’s words, NCT03020992 on ClinicalTrials.gov
- Tested for
- Rheumatoid Arthritis (4 trials), Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU), Psoriasis, Plaque Psoriasis, Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA and 8 more
- Main trialPhase 4
- “The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.”In the company’s words, NCT03020992 on ClinicalTrials.gov
- Other names
- Cimzia · CDP870 · CZP · MTX
Other drugs for Rheumatoid Arthritis
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 4 Dec 2019 | A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU | |
| Phase 3Completed | 28 Aug 2013 | Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis | |
| Phase 3Completed | Jul 2014 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis | |
| Phase 3Completed | Jul 2015 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis | |
| Phase 3Completed | 22 Mar 2016 | Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) | |
| Phase 3Completed | May 2018 | Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS | |
| Phase 3Withdrawn | Sep 2023 | A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease | |
| Phase 3Completed | 8 Apr 2024 | Pediatric Arthritis Study of Certolizumab Pegol | |
| Phase 3Completed | 9 Apr 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 2/3Completed | 19 Nov 2018 | A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis | |
| Phase 2Completed | 25 May 2020 | A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis | |
| Phase 1Completed | 24 Jan 2022 | A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 4Ended | not given | PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach | |
| Phase 3Authorised | not given | Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial (CERTIFY) | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 4Authorised | not given | A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment. | |
| Phase 3Authorised | not given | A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE) | |
| Phase 4Authorised | not given | Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference | |
| Phase 4Authorised | not given | DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026